Patient characteristics and outcomes
| . | Total (N = 189) . | 16S rRNA (n = 158) . | Shotgun (n = 106) . |
|---|---|---|---|
| n (%) . | n (%) . | n (%) . | |
| Baseline characteristics | |||
| Sex | |||
| Male | 119 (63) | 101 (64) | 63 (59) |
| Female | 70 (37) | 57 (36) | 43 (41) |
| Age, y | |||
| ≤60 | 98 (52) | 83 (53) | 61 (58) |
| >60 | 91 (48) | 75 (47) | 45 (42) |
| BMI, kg/m2 | |||
| <25 | 125 (66) | 104 (66) | 70 (66) |
| ≥25 | 64 (34) | 54 (34) | 36 (34) |
| ECOG PS | |||
| 0 | 144 (76) | 121 (76) | 78 (74) |
| 1 | 44 (23) | 37 (23) | 28 (25) |
| 2 | 1 (1) | 1 (1) | 1 (1) |
| B symptoms | |||
| Presence | 7 (4) | 5 (3) | 4 (4) |
| Absence | 182 (96) | 153 (97) | 102 (96) |
| Serum LDH | |||
| Elevated | 90 (48) | 74 (47) | 47 (44) |
| Normal | 99 (52) | 84 (53) | 59 (56) |
| β2-microglobulin | |||
| Elevated | 30 (16) | 23 (15) | 16 (15) |
| Normal | 137 (72) | 122 (77) | 80 (76) |
| Not examined | 22 (12) | 13 (8) | 10 (9) |
| CRP | |||
| Elevated | 73 (39) | 61 (39) | 38 (36) |
| Normal | 96 (51) | 81 (51) | 54 (51) |
| Not examined | 20 (10) | 16 (10) | 14 (13) |
| Cell of origin | |||
| ABC | 102 (54) | 83 (53) | 57 (54) |
| GCB | 61 (32) | 54 (34) | 36 (34) |
| Not determined | 26 (14) | 21 (13) | 13 (12) |
| Stage | |||
| I/II | 109 (58) | 94 (60) | 57 (54) |
| III/IV | 80 (42) | 64 (40) | 49 (46) |
| Bone marrow | |||
| Involved | 12 (6) | 11 (7) | 9 (9) |
| Not involved | 155 (82) | 132 (84) | 84 (79) |
| Not examined | 22 (12) | 15 (9) | 13 (12) |
| IPI | |||
| Low | 95 (50) | 83 (53) | 55 (52) |
| Low-intermediate | 40 (21) | 34 (21) | 23 (22) |
| High-intermediate | 35 (19) | 27 (17) | 17 (16) |
| High | 19 (10) | 14 (9) | 11 (10) |
| Treatment outcome after RCHOP | |||
| Complete response | 171 (90) | 146 (92) | 101 (95) |
| Partial response | 9 (5) | 8 (5) | 5 (5) |
| Progression | 4 (2) | 4 (3) | |
| Not evaluated | 5 (3) | ||
| Febrile neutropenia | 39 (21) | 30 (19) | 23 (22) |
| Disease relapse during follow-up | 20 (11) | 17 (11) | 11 (10) |
| . | Total (N = 189) . | 16S rRNA (n = 158) . | Shotgun (n = 106) . |
|---|---|---|---|
| n (%) . | n (%) . | n (%) . | |
| Baseline characteristics | |||
| Sex | |||
| Male | 119 (63) | 101 (64) | 63 (59) |
| Female | 70 (37) | 57 (36) | 43 (41) |
| Age, y | |||
| ≤60 | 98 (52) | 83 (53) | 61 (58) |
| >60 | 91 (48) | 75 (47) | 45 (42) |
| BMI, kg/m2 | |||
| <25 | 125 (66) | 104 (66) | 70 (66) |
| ≥25 | 64 (34) | 54 (34) | 36 (34) |
| ECOG PS | |||
| 0 | 144 (76) | 121 (76) | 78 (74) |
| 1 | 44 (23) | 37 (23) | 28 (25) |
| 2 | 1 (1) | 1 (1) | 1 (1) |
| B symptoms | |||
| Presence | 7 (4) | 5 (3) | 4 (4) |
| Absence | 182 (96) | 153 (97) | 102 (96) |
| Serum LDH | |||
| Elevated | 90 (48) | 74 (47) | 47 (44) |
| Normal | 99 (52) | 84 (53) | 59 (56) |
| β2-microglobulin | |||
| Elevated | 30 (16) | 23 (15) | 16 (15) |
| Normal | 137 (72) | 122 (77) | 80 (76) |
| Not examined | 22 (12) | 13 (8) | 10 (9) |
| CRP | |||
| Elevated | 73 (39) | 61 (39) | 38 (36) |
| Normal | 96 (51) | 81 (51) | 54 (51) |
| Not examined | 20 (10) | 16 (10) | 14 (13) |
| Cell of origin | |||
| ABC | 102 (54) | 83 (53) | 57 (54) |
| GCB | 61 (32) | 54 (34) | 36 (34) |
| Not determined | 26 (14) | 21 (13) | 13 (12) |
| Stage | |||
| I/II | 109 (58) | 94 (60) | 57 (54) |
| III/IV | 80 (42) | 64 (40) | 49 (46) |
| Bone marrow | |||
| Involved | 12 (6) | 11 (7) | 9 (9) |
| Not involved | 155 (82) | 132 (84) | 84 (79) |
| Not examined | 22 (12) | 15 (9) | 13 (12) |
| IPI | |||
| Low | 95 (50) | 83 (53) | 55 (52) |
| Low-intermediate | 40 (21) | 34 (21) | 23 (22) |
| High-intermediate | 35 (19) | 27 (17) | 17 (16) |
| High | 19 (10) | 14 (9) | 11 (10) |
| Treatment outcome after RCHOP | |||
| Complete response | 171 (90) | 146 (92) | 101 (95) |
| Partial response | 9 (5) | 8 (5) | 5 (5) |
| Progression | 4 (2) | 4 (3) | |
| Not evaluated | 5 (3) | ||
| Febrile neutropenia | 39 (21) | 30 (19) | 23 (22) |
| Disease relapse during follow-up | 20 (11) | 17 (11) | 11 (10) |
ABC, activated B cell; BMI, body mass index; CRP, C-reactive protein; GCB, germinal-center B cell; PS, performance status.